Reading KALA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KALA free→Reading KALA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KALA free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral. Earnings quality cannot be assessed since the company is unprofitable. Management's recent track record has been unsteady, with frequent changes. Risk is high, and the sector backdrop is a headwind. Peer multiples imply a price about 83% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern suggests potential issues due to weak financials or fragile earnings quality. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $3.14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $3.14 KALA trades at 3× p/s, below its 10× p/s peer median. Our $14 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 87% below a flat-multiple fair value, below our forecast of about -1%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 1.33x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
34 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$476.
How much price usually moves either way.
On a bad day, this stock has moved -$1,302.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $9,979.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for KALA yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Material Modification to Rights of Security Holders. To the extent required by
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus peers.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
KALA KALA BIO INC | Typical Show detailsSector percentile: 31 of 100 | inexpensive | high |
Not investment advice. As of 2026-06-16.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
KALA BIO obtained a worldwide exclusive license for Younet's AI research platform.
KALA BIO made a material modification to the rights of its security holders.
KALA BIO engaged in unregistered sales of equity securities.
Entry into a Material Definitive Agreement. On March 3, 2026 (the “Effective Date”), KALA BIO, Inc. (the “Company”) and 2624465 Ontario Inc. o/a Younet AI, an Ontario corporation (“Younet”) entered into a Platform Development and Exclusive License Agreement (the “Agreement”) pursuant to which the Company obtained a worldwide exclusive license (the “Exclusive License”) of Younet’s proprietary, custom biomedical artificial intelligence research platform (the “Researgency Platform”), together wi…
Unregistered Sales of Equity Securities. The matters described in
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On February 2, 2026, David Lazar tendered his resignation to the Board of the Directors (the “ Board ”) as the Chief Executive Officer and Chief Financial Officer of KALA BIO, Inc. (the “ Company ”), effective as of the same date. Mr. Lazar remains a director of the Board. On February 2, 2026, to fill the executive vacancy as a result of Mr. Lazar’s resignation as the Chief Executive Office…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On February 16, 2026, David Lazar notified KALA BIO, Inc. (the “ Company ”) of his decision to resign as a member of the Board of Directors of the Company, effective as of the same date. Mr. Lazar’s resignation from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices. 1 SIGNATURE Pursuant to the requirements of the S…